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Abstract. In vivo analyses of pharmacological data are traditionally based on a closed
system approach not incorporating turnover of target and ligand-target kinetics, but mainly
focussing on ligand-target binding properties. This study incorporates information about
target and ligand-target kinetics parallel to binding. In a previous paper, steady-state
relationships between target- and ligand-target complex versus ligand exposure were derived
and a new expression of in vivo potency was derived for a circulating target. This
communication is extending the equilibrium relationships and in vivo potency expression
for (i) two separate targets competing for one ligand, (ii) two different ligands competing for
a single target and (iii) a single ligand-target interaction located in tissue. The derived
expressions of the in vivo potencies will be useful both in drug-related discovery projects and
mechanistic studies. The equilibrium states of two targets and one ligand may have
implications in safety assessment, whilst the equilibrium states of two competing ligands for
one target may cast light on when pharmacodynamic drug-drug interactions are important.
The proposed equilibrium expressions for a peripherally located target may also be useful for
small molecule interactions with extravascularly located targets. Including target turnover,
ligand-target complex kinetics and binding properties in expressions of potency and efficacy
will improve our understanding of within and between-individual (and across species)
variability. The new expressions of potencies highlight the fact that the level of drug-induced
target suppression is very much governed by target turnover properties rather than by the
target expression level as such.




In this paper, we continue our study of in vivo potency of
drug-target kinetics begun in Gabrielsson, Peletier et al. and
Hjorth et al. (1,2) in the framework of Target-Mediated Drug
Disposition (TMDD), an ubiquitous process in the action of
drugs that has been extensively studied ever since the
pioneering papers of Wagner (3), Sugiyama et al. (4) and Levy
(5). We also refer to the seminal papers by Michaelis and
Menten (6), Mager and Jusko (7), Mager and Krzyzansky (8),
Gibiansky et al. (9) and Peletier and Gabrielsson (10). In Fig. 1,
we show schematically the basic TMDD model: Ligand is
supplied to the central compartment where it binds a receptor
(the target) resulting in a ligand-receptor complex, which
internalises to produce a pharmacologial response. In addition,
ligand is cleared from the central compartment and exchanged
with a peripheral compartment. Target is synthesised by a zeroth
order process and degrades by a first-order process.
In this paper, we extend the results for this TMDD
model obtained in (1) to three generalisations of the TMDD
model in which (i) the drug can bind two receptors (cf. 11),
(ii) two drugs can bind one receptor (cf. 12) and (iii) the dug
is supplied to the central compartment, but the receptor is
located in the peripheral compartment (cf. 13).
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Mathematically, the basic TMDD model, depicted in Fig. 1,




















¼ ksyn−kdegR−konLc  Rþ koffRL
dRL
dt






Here, Lc and Lp denote the concentrations of ligand (or
drug) in, respectively, the central and the peripheral com-
partment with volumes Vc and Vp. Concentrations of target
and target-ligand complex in the central compartment are
denoted by R and RL. Drug infusion takes place into the
central compartment, with constant rate In where it binds to
the target with rates kon and koff. Ligand is removed through
non-specific clearance Cl(L) and exchanged with the periph-
eral compartment through inter-compartmental distribution
Cld. By internalisation, ligand-target complex leaves the
system according to a first-order process with a rate constant
ke(RL). Finally, target synthesis and degradation are modelled
by, respectively, zeroth- and first-order turnover with rates
ksyn and kdeg.
We recall the analysis presented in (1) for the one-
compartment TMDD-model shown in Fig. 1. There, relations
between steady-state concentrations of target R, ligand L and
complex RL were derived, and a new expression of the
in vivo potency, denoted by L50, was established, particularly
suited for Open Systems. Whereas the classical definition of
potency is primarily based on the binding constants (cf. Black
and Leff (14), Kenakin (15,16), Neubig et al. (17)) and target
expression, in the definition of, in vivo potency drug and
target kinetics, such as the degradation rate kdeg, are also
incorporated. These concepts were further discussed from an
open and closed system perspective in (2).
In this paper, we present three generalisations of the
classical TMDD model: (i) a single ligand that can bind two
receptors R1 and R2, (ii) two ligands, L1 and L2, that compete
for a single receptor and (iii) a ligand that is supplied to the
central compartment and distributed to the peripheral
compartment where the target is located.
Steady States
In (1), it has been established how for the model shown
in Fig. 1, the steady-state values of ligand (L), receptor (R)
and ligand-receptor complex (RL), in the central compart-
ment, are related to one another:
RL ¼ R  L
Lþ L50 and R ¼ R0 
L50
Lþ L50 ð2Þ
where the baseline R0, the maximal impact R
∗ and the in vivo
potency EC50 (denoted by L50) are given by
R0 ¼ ksynkdeg ; R
 ¼ ksyn
ke RLð Þ
and L50 ¼ kdegke RLð Þ
Km ð3Þ
and Km = (koff + ke(RL))/kon is called the Michaelis-Menten
constant. Here, it is implicitly assumed that the constant rate
infusion, In, is fixed at the appropriate value. In (1), the
required infusion rate is also computed.
The definition of the in vivo potency, L50, expresses both
the impact of rate processes of the target (kdeg, ke(RL)) and
those of the binding dynamics (koff, kon), on the drug
concentration (L) required to achieve the desired efficacy.
The resemblance of Eq. (2) with the Hill equation
(below) is striking.




The Hill equation is often used in vivo and also contains
a baseline parameter E0 in addition to the maximum drug
induced effect Emax and the potency EC50. Equation (2) has
intrinsically the baseline in terms of R0. The Emax parameter
is equivalent to ∣RLmax −R0∣, and the potency parameter
EC50 is expressed in Eq. (3) as L50.
The exponent nH of the Hill equation is interpreted as a
fudge factor allowing the steepness of the Hill equation at the
EC50 value to vary. In our experience nH is not necessarily an
integer and varies typically within the range of 1–3. We have
observed with high and variable plasma protein binding that
nH will change depending on whether unbound or total
plasma concentration (respectively Cu and Ctot) is used as
drivers of the pharmacological effect.
Remark. It is interesting to note that Eq. (3) yields the
following relation between the baseline target concentration,
R0, the maximal ligand-target concentration, R
∗, and the
in vivo potency L50:
L50  R0 ¼ Km  R ð4Þ
This means that if the baseline of target, the maximum ligand-
target concentration and Km are obtained experimentally,
then the in vivo potency L50 can be predicted. Thus, Km can
be located either to the right or to the left of the in vivo
potency, depending on the relative magnitude of R0 and R
∗.
In Fig. 2, we show graphs for RL and R versus L for two
parameter sets, one taken from Peletier and Gabrielsson (10)
Fig. 1. Schematic description of the model for Target Mediated Drug
Disposition involving ligand in the central compartment (Lc) and in
the peripheral compartment (Lp) binding a receptor (R) (the target),
yielding ligand-target complexes (RL)
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(left) and one from Cao and Jusko (18) (right) (cf. Appendix
2; Tables I and II).
The values of R0, R
∗ and L50 that appear in Eq. (2) are
for these two references given by
R0 ¼ 12; R ¼ 36 L50 ¼ 0:13 Peletier and Gabrielsson 10½ 
R0 ¼ 10 R ¼ 3:3 L50 ¼ 0:10 Cao and Jusko 18½ 
ð5Þ
Thus, remembering that initially, R =R0 and RL = 0, it is
evident that over time, the system settles into a steady state,
in (10) where total target concentration exceeds R0 and in
(18) where target concentration is less than target baseline.
It is interesting to note that despite similar in vivo
potency’s (L50’s) of Cao and Jusko and Peletier and
Gabrielsson, the target-to-complex ratios differ by one order
of magnitude due to the comparable difference in ke(RL).
The proposed framework with a dynamic target protein
may also be applicable to enzymatic reactions which may
enhance the in vitro/in vivo extrapolation of metabolic data
(cf Pang et al. 19,20).
Discussion and Conclusions
Eqs. (2) and (3) summarise what is needed to apply and
explain target R, ligand-target RL and ligand L interactions
when both ligand and target belongs to the central (plasma)
compartment. Equation (3) clearly demonstrates that in vivo
potency, a central parameter in pharmacology, is a conglom-
erate of target turnover, complex kinetics and ligand-target
binding properties.
In the following three sections, we discuss generalisations
of the basic TMDD model discussed in BINTRODUCTION^
and derive generalisations of the functions RL = f(L) and R =
g(L) applicable to these models.
TWO DIFFERENT RECEPTORS COMPETE FOR ONE
LIGAND
Background
When one ligand, L, can bind two receptors, R1 and R2,
two complexes are formed and internalised to form two
different ligand-receptor complexes R1L and R2L; it is of
great value to determine their relative impact on the
pharmacological response, and it is important to determine
how the responses of these two complexes are related. For
instance, when one receptor mediates a beneficial effect of a
drug and the other one mediates an adverse effect, one
wishes to know the relative impact of the latter target and
whether the two potencies EC50; 1 and EC50; 2 are sufficiently
well separated so that a dose can be selected with minimally
adverse effect. Figure 3 gives a schematic description of the
model.
Mathematically, the model shown in Fig. 3 can be




¼ kinfus−ke Lð ÞL−kon;1L  R1 þ koff;1R1L
−kon;2L  R2 þ koff;2R2L
dR1
dt
¼ ksyn;1−kdeg;1R1−kon;1L  R1 þ koff;1R1L
dR1L
dt





¼ ksyn;2−kdeg;2R2−kon;2L  R2 þ koff;2R2L
dR2L
dt






in which the parameters are defined as in the system (1) and




For a related model, with a corresponding system of
Fig. 2. RLss and Rssversus Lss for the parameter values of Peletier and Gabrielsson (10) (left) and Cao and Jusko (18)
(right). The parameter values are given in Tables I and II in Appendix 2
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equations, we refer to (11). By adding the equations for free
receptors R1 and R2 to the equations for the associated bound
receptors R1L and R2L, we obtain two balance equations for,
respectively, R1 and R2:
d
dt
R1 þ R1Lð Þ ¼ ksyn;1−kdeg;1R1−ke R1Lð ÞR1L
d
dt
R2 þ R2Lð Þ ¼ ksyn;2−kdeg;2R2−ke R2Lð ÞR2L
8><
>: ð8Þ
For ligand, free or bound to one of the two receptors, we
obtain the balance equation:
d
dt
Lþ R1Lþ R2Lð Þ ¼ kinf−ke Lð ÞL−ke R1Lð ÞR1L−ke R2Lð ÞR2L ð9Þ
Steady States
As in the case of a single target, it is possible to obtain
expressions for the concentrations of ligand-target complex
and free target, i.e. for RiL and Ri (i = 1, 2) in terms of the
ligand concentration L.
Following the steps taken in Gabrielsson and Peletier
(1), it is possible to show that for the receptors individually,
the expressions such as shown in (2) hold





for i = 1 and i = 2.
The baseline receptor concentrations R0. i, the maximum
values Ri of the receptor-ligand complexes and the in vivo
potencies L50; i are given by





; L50;i ¼ kdeg;ike RiLð Þ
Km;i ð11Þ
for i = 1 and i = 2.
where Km;i ¼ koff;i þ ke RiLð Þ
 
=kon;i. Details of the derivations
of the formulas above are presented in Appendix 1.1.
Figure 4 shows the target suppression and complex
formation of the two targets versus ligand concentration at
equilibrium together with their respective L50 values. These
graphs are useful in discriminating between two targets and
deciding which target contributes most to complex formation
at different ligand concentrations. The left figure shows the
Fig. 3. Schematic description of a model for the one-compartment two-target system in which ligand binds
with two receptors R1 and R2, each forming a complex denoted by, respectively, R1L and R2L. The
definition of parameters is the same as in Fig. 1
Fig. 4. Target suppression (left) and ligand-target complex (right) versus ligand concentration for two receptors R1 and R2.
The parameter values for the two receptors are given in Table II in Appendix 2. The dashed lines indicate the corresponding
values for L50: L50;1 = 4.34 nM and L50;2 = 2.18 nM
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two target suppression curves R1 and R2versus ligand and the
right figure the two ligand-target complexes R1L and R2L
versus ligand L. The parameter values are chosen fictitiously
in order to clearly highlight the differences (Table III,
Appendix 2).
The model shown in Fig. 3 has been used as a two-state
model to fit the data for the total free target concentration
that were given in Gabrielsson and Weiner (PD2) p. 729 (21).
The total free target concentration, i.e. R1 +R2, can be
computed from Eq. (10) and (11) and is seen to be
Rfree;tot ¼ R1 þ R2 ¼ R0:1  L50;1Lþ L50;1 þ R0:2 
L50;2
Lþ L50;2 ð12Þ
Evidently, in the absence of ligand, Rfree; tot =R0.1 +R0.2,
while Rfree; tot→ 0 as L→∞.
In Fig. 5, we see how the model is fitted to data obtained
from an experiment involving four total target concentrations
(Rtot = 8050, 6510, 3540 and 1590 nM). As the ligand
concentration increases, the first receptor kicks in at the
lowest in vivo potency (0.025 nM), taking the free receptor
concentration down to a lower intermediate plateau. Then, at
the higher in vivo potency (37 nM), the free receptor
concentration drops further and eventually converges to zero.
Remark. The parameters kdeg, ke(RL), kon and koff are not
given here since only equilibrium data from the experiments
were available. Due to parameter unidentifiability, the model
was parametrised with potencies L50; 1 and L50; 2 as
parameters and not functions of their original determinants.
One may also need other sources of information to fully
appreciate the actual values of kdeg, ke(RL), kon and koff.
In vitro binding experiments may yield kon and koff. In vivo
time courses of circulating free ligand, target and ligand-
target are necessary in order to estimate ke(RL). Information
about the kdeg parameter may be found in the literature for
commonly studied targets.
Discussion and Conclusion
Here, Eq. (10), (11) and (12) summarise what is needed
to apply and explain target Ri, ligand-target RiL and ligand L
interactions when ligand and both targets belong to the
central (plasma) compartment. Equation (11) demonstrates
again the complexity of in vivo potencies L50; i involving both
turnover of the two targets, complex kinetics and ligand-
target binding properties.
The explicit expressions for the ligand-receptor com-
plexes RiL, the free receptor concentrations Ri and the
in vivo potencies L50; i (cf. (12)), together with Figs. 4 and
5, provide valuable tools when assessing the individual
contribution of each target and specifically the impact of
target turnover and internalisation.
TWO DIFFERENT LIGANDS COMPETING FOR ONE
RECEPTOR
Background
A common situation, for instance in combination ther-
apy, is that not one but two ligands L1 and L2 bind a single
receptor R. This results in two different complexes, RL1 and
RL2, with different internalisation rates. For instance, one of
the ligands is produced endogenously, and the other is a drug
which is supplied in order to inhibit or stimulate the
pharmacological effect caused by the endogenous ligand (cf.
Benson et al. 22,23).
Recently, several authors have derived different drug-
drug interaction models associated with TMDD with a
Fig. 5. Total free target level Rtot;free=R1 +R2 and model predicted graphs (solid lines) of
Rtot;freeversus L for four total receptor concentrations (Rtot = 8050, 6510, 3540 and 1590 nM)
andR0,1 =Rtot ·F andR0,2 =Rtot · (1−F) with F= 0.6 Note the wide discrepancy between the
two in vivo potenciesL50;1 (denoted in the figure by IC50;1)(0.025 nM) andL50;2 (denoted in the
figure by IC50;2) (37 nM). The high affinity drug is the target for therapeutic effect, and the low
affinity drug is responsible for an adverse effect (cf. Gabrielsson andWeiner, PD2, page 729 21)
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different focus and often directed towards the situation when
a constant target level prevails (cf. Koch et al. (24,25) and
Gibiansky et al. (26)). In order to describe open, in vivo,
processes, it is necessary to include target turnover,
internalisation and drug clearance. This is done in the model
shown in Fig. 6 in which two ligands, distinguished by
subscripts i = 1 and 2, are supplied by constant-rate infusions
Ini to the central compartment, each having its own volume of
distribution Vci, nonspecific clearance Cl Lið Þ, binding and
dissociation rate kon; i and koff; i, and its own internalisation
rate ke RLið Þ.
Mathematically, the model shown in Fig. 6 can be
described by the following system of differential equations
for the two ligands, L1 and L2, the target R and the two
ligand-target complexes RL1 and RL2 (see also (12)):
dL1
dt
¼ kinfus;1−ke L1ð ÞL−kon;1L1  Rþ koff;1RL1
dL2
dt
¼ kinfus;2−ke L2ð ÞL−kon;2L2  Rþ koff;2RL2
dR
dt
¼ ksyn−kdegR−kon;1L1  Rþ koff;1RL1
−kon;2L2  Rþ koff;2RL2
dRL1
dt












kinfus;i ¼ IniVc and ke Lið Þ ¼
Cl Lið Þ
Vc
; i ¼ 1; 2ð Þ ð14Þ
Each of the ligands is present in free form (Li) and in
bound form (RLi) (i = 1, 2). For the total amount of the two




L1 þ RL1ð Þ ¼ kinfus;1−ke L1ð ÞL1−ke RL1ð ÞRL1
d
dt
L2 þ RL2ð Þ ¼ kinfus;2−ke L2ð ÞL2−ke RL2ð ÞRL2
8><
>: ð15Þ
The receptor is present in free form (R) and in bound
form (RLi). Adding the last three equations of the system




Rþ RL1 þ RL2ð Þ
¼ ksyn−kdegR−ke RL1ð ÞRL1−ke RL2ð ÞRL2 ð16Þ
These balance equations will be useful for analysing
steady-state concentrations, when the left-hand sides vanish
and we obtain three algebraic equations.
Steady States
We deduce from Eq. (16) that the steady-state concen-
trations R, RL1 and RL2 are related by the equation
ksyn−kdegR−ke RL1ð ÞRL1−ke RL2ð ÞRL2 ¼ 0 ð17Þ
This allows us to express R in terms of the concentrations
of the two complexes, RL1 and RL2:
R ¼ 1
kdeg








when we use the short-hand notation
X1 ¼ ke RL1ð ÞRL1 and X2 ¼ ke RL2ð ÞRL2 ð20Þ
We substitute the expression for R in Eq. (19) into the right-
hand side of each of the last two equations of Eq. (13) to
obtain:
L1  1kdeg ksyn−X1−X2
  ¼ Km;1 X1ke RL1ð Þ
L2  1kdeg ksyn−X1−X2





koff ;i þ ke RLið Þ
kon;i
Fig. 6. Schematic description of the competitive-interaction model in
which a single target R binds two ligands L1 and L2, forming two
complexes denoted by, respectively, RL1 and RL2
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This is an algebraic system of two equations with two
unknowns, X1 and X2, which can be solved. Translating these
solutions back to the original variables, we obtain the
following expressions for RL1 and RL2:
RL1 ¼ R1
L1
L1 þ θ  L2 þ L50;1
RL2 ¼ R2
L2
L2 þ θ−1  L1 þ L50;2
8>><
>: ð22Þ
where L50; 1 and L50; 2 are given by




and θ ¼ L50;1
L50;2
ð23Þ
for i = 1 and i = 2.
The expressions for the complexes RL1 and RL2 can be
used in Eq. (18) to derive an expression for R in terms of the
two ligand concentrations:
R ¼ R0 1− L1L1 þ θ  L2 þ L50;1−
L2
L2 þ θ−1  L1 þ L50;2
 !
ð24Þ
where θ =L50; 1/L50; 2. Thus, the impact of the two ligand
combined is seen to be additive.
Details of the derivations of the equations above are
given in Appendix 1.2.
In the expressions for RL1 in Eq. (22), one can interpret
the term (θ ·L2 +L50; 1) in the numerator as a shift of potency
L50; 1, and similarly in the expression for RL2, the term (θ
−1 ·
L1 +L50; 2) can be viewed as a shift of potency L50; 2. Thus,
the modifications of the potencies L50; 1 and L50; 2 (equivalent
to EC50; 1 and EC50; 2) depend on the ligand concentrations in
the following manner:
EC50;1↗ when L2↗
i.e. EC50; 1increases when L2increases. Similarly, EC50;2
increases when L1 increases.
Note that by Eq. (22), when L2 is arbitrary but fixed,
then
RL1 L1;L2ð Þ→ 0 as L1→0RL1→R1 as L1→∞

ð25Þ
In the context of an endogenous ligand (L1) and a drug
(L2) which is administered to reduce the effect of the
endogenous ligand, Eq. (22) is of practical value. Assuming
that receptor occupancy RL1 is a measure for the effect of L1,
it tells by how much the effect of L1 is reduced by a given
concentration of L2.
Finally, we observe that
RL1 L1;L2ð Þ →R1
L1
L1 þ L50;1 as L2→0
RL2 L1;L2ð Þ →R2
L2
L2 þ L50;2 as L1→0
8><
>: ð26Þ
These limits are consistent with the expression in Eq. (2)
for a single receptor shown in BINTRODUCTION^. Plainly,
RL1(L1,L2) = 0 when L1 = 0 and RL2(L1,L2) = 0 when L2 = 0.
It is illustrative to view the two complexes and the total
free drug concentration as they depend on both ligand
concentrations: L1 and L2. This is done in Fig. 7 where 3D
graph of R versus L1 and L2 is shown as well as the
corresponding Heat map. In both graphs, R0 = 100, L50; 1 =
50 and L50; 2 = 25 are taken so that θ = 2.As we see
R L1;L2ð Þ →R0 ¼ 100 as L1;L2ð Þ→ 0; 0ð Þ
R L1;L2ð Þ →RL1 0;L2ð Þ ¼ 0 as L1→0 :

ð27Þ
Fig. 7. Graphs of R versus L1 and L2 according to Eq. (24). Here, R0 = 100, L50;1 = 50 and L50;2 = 25 so that θ = 2. Note that
the level curves are straight lines with slope L1/L2 = − 2
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These limits are in agreement with the Eq. (22) for RL1
and Eq. (25) for R.
Discussion and Conclusion
Equations (22), (23) and (24) summarise what is
needed to apply and explain target R, ligand-target
complex RLi and ligand Li interactions when two ligands
interact with one centrally located target. Equation (23)
clearly demonstrates that in vivo potency is a conglomerate
of target turnover, complex kinetics and ligand-target
binding properties.
TARGET IN THE PERIPHERAL COMPARTMENT
Background
When ligand and target are located in the central
compartment of the TMDD model, the steady-state relations
of ligand, target and ligand-target complex have been derived
in Gabrielsson and Peletier (1) and briefly summarised in the
BIntroduction^ (cf Eqs. (2) and (3)). In this section, we
generalise this situation to when ligand is supplied to the
central compartment, but target is located in the peripheral
compartment so that ligand has to be cleared from the central
compartment into the peripheral compartment before it can
bind the target.
We assume active transport between the two com-
partments, as may be caused by blood flow or trans-
porters, and denote clearance from the central
compartment by Cldα and from the peripheral compart-
ment by Cldβ. These two processes allow concentration
differences to build up across the membrane separating
the two compartments..
The objective is here to derive expressions for the
concentration of free receptor R and ligand-receptor complex
RLp in the peripheral compartment and the ligand concen-
tration Lc in the central compartment.
Figure 8 gives a schematic description of the model we
study.



















−konLp  Rþ koffRLp
dR
dt
¼ ksyn−kdegR−konLp  Rþ koffRLp
dRLp
dt






For convenience, we shall often write









The system (28) yields the following balance equations
for the target and the ligand:
& For the target, which involves free target R and
bound target RLp: By adding the third and fourth




  ¼ ksyn−kdegR−ke RLpð ÞRLp ð30Þ
& For the ligand, which involves Lc, Lp and RLp:
By adding the first equation in Eq. (28) and the sum
of the second and the fourth equation multiplied by
μ =Vp/Vc, we obtain
d
dt
Lc þ μ Lp þ RLp
   ¼ kinfus−kdeg R−μ  ke RLpð ÞRLp ð31Þ
Steady States
An expression for the concentration of ligand-target
complex in terms of the ligand concentration in the peripheral
compartment Lp can be derived in a manner which is
Fig. 8. Schematic description of the model for Target Mediated Drug Disposition involving
ligand in the central compartment (Lc) and in the peripheral compartment (Lp) binding a
receptor (R) (the target), located in the peripheral compartment yielding ligand-target
complexes (RLp)
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analogous to the one employed before for the one-
compartment model and yields the following equation:
RLp ¼ ksynke RLpð Þ
Lp




Note that the expression for Lp; 50 is the same as the one
defined for L50 in Eq. (3).
Next, we replace Lp in the expression for RLp by Lc. By
adding the second and the fourth equation of the system (Eq.
(28)), we express Lp in terms of Lc and RLp:
Lp ¼ 1kpc μ
−1 kcp Lc−ke RLpð ÞRLp
n o
: ð33Þ
When we use this equation in Eq. (32) to replace Lp by Lc,
we arrive at an expression which only involves Lc and RLp.
Specifically, putting X ¼ ke RLpð ÞRLp, we obtain






Equation (34) provides an expression for Lc as a function
of X, i.e. Lc = f(X). It is seen that the function f(X) is
monotonically increasing so that it can be inverted to give an
expression of X in terms of Lc and so yield the desired
expression of RLp in terms of Lc.
In order to invert the function f(X), we multiply Eq. (34)
by (ksyn −X) and so obtain a quadratic equation in X:
X2− ksyn þ aLc þ b
 




¼ kpc and b ¼ kpckdegke RLpð Þ
⋅ km ð36Þ
The roots of this equation are
X ¼ 12 ksyn þ aLc þ b




Obviously, we need the root which vanishes when Lc = 0,
i.e. we need X−. Therefore
RLp ¼ 12 ke RLpð Þ




ksyn þ aLc þ b




The corresponding expression for target depression in







aLc þ bð Þ−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ksyn þ aLc þ b




A more detailed derivation of these expressions for the
concentration of ligand-receptor complex in terms of the
ligand concentration in plasma can be found in the Appendix
1.1 (A.3 and A.4).
On the basis of the implicit expression (34) of X (i.e.
RLp) in terms of Lc, it is also possible to define Lc; 50. Plainly,
at Lc; 50, we have X = ksyn/2, i.e. RLp =R
∗/2. When we
substitute this value for X into Eq. (34), we obtain the

















where we have used the definition of Lp; 50 in Eq. (32).
Passive Transport Between Central and Peripheral
Compartment
If distribution between the two compartments is passive,





Observation. Equation (40) immediately implies that
Cldβ > Cldα ⟹ Lc;50 > Lp;50 ð41Þ
If target-synthesis is small compared to in- and out-flow
of ligand between the two compartments, the reverse
inequalities are seen to hold as well.
It follows from this expression that Lc, 50increases when
transport from the central towards the peripheral compart-
ment becomes harder (Cldα↗) and vice versa, it decreases
when it becomes easier (Cldβ↘).









then, the expression (Eq. (40)) reduced to a particularly
simple relation between Lc; 50 and Lp; 50:





in which the relative impact of the two clearances becomes
very transparent.
The expression (Eq. (37)) for RLp in terms of Lc is fairly
complex and not so easy to grasp. However, it is possible to
derive a few properties of the dependence of RLp on Lc
without going to the details of an explicit computation based
on Eq. (37). Below we give a few examples.
1. It follows from Eq. (37) that 0 <X < ksyn. Therefore,





regardless of the ligand concentration Lc in the central
compartment.
2. It is clear from Eq. (34) that Lc is an increasing
function of X. Therefore, RLp is an increasing
function of Lc:
RLp Lcð Þ↗R as Lc→∞ ð45Þ
Note that in Eqs. (44) and (45), the active transport
between the central and the peripheral compartment (the
parameters α and β) do not come into the upper bound and
the limit for large Lc.
In Fig. 9, we show graphs of R and RLpversus Lc for
three values of the clearance into the peripheral compartment
Cldα (α = 0.001, α = 1 and α = 100), whilst reverse clearance,
from the peripheral compartment into the central compart-
ment is fixed. As predicted by Eq. (40), the potency Lc;
50decreases as α increases and hence when kcp decreases. Of
course, this is understandable: When transport to the
peripheral compartment becomes easier, drug reaches its
target more easily, less of it is required to achieve the same
effect and the in vivo potency increases.
Comparing the graphs of the concentration of the ligand-
target complex RLpversus the ligand concentration in the
central compartment Lc in Figs. 2 and 9, the latter, when
target is located peripherally, shows up to be (i) asymmetrical
and (ii) to exhibit a shift between the central and peripheral
concentrations.
Discussion and Conclusions
Equations (32), (37), (38) and (39) summarise what is
needed to apply and explain target R, ligand-target complex
RLp and ligand L (Lc and Lp) interactions when the target is
peripherally located. The effect of the permeability of the
membrane between central and peripheral compartment and
the volumes of these compartments show up explicitly in the
expression for the in vivo potency given in Eq. (39) in
combination with target turnover and ligand-target binding
properties. This explicit expressions make it possible to give
quantitative estimates.
DISCUSSION AND CONCLUSIONS
In Vivo Potency—the Role of Target Dynamics
The new concept of potency discussed in this paper
departs from the previous one, based on the assumption
that the actual expression level of target rather than its
turnover rate will determine the potency. Thus, looking at
the data of two individuals with the same target expres-
sion level (concentration), one would assume that the two
individuals would require the same drug exposure. In
these papers, we have shown that in fact, this need not be
Fig. 9. Sensitivity graphs of R and RLpversus Lc, on a semi-logarithmic scale, with regard to the clearance rate from the
central to the peripheral compartment αCld where α = 0.1,1,10 and the clearance rate from peripheral to central
compartment βCd is fixed (β = 1). Other parameters are listed in Table I
69 Page 10 of 15 The AAPS Journal (2018) 20: 69
true. Instead, according to the definition of L50, the
subject with the higher target elimination rate (kdeg) will
need more drug compared to a subject with a slow target
turnover rate, whilst the subject with the higher
internalisation rate (ke(RL)) will require less drug.
kdeg;A < kdeg;B⟹L50;A < L50;B
Expressed mathematically, we demonstrated how the
potency L50 is given in open as opposed to closed systems by
the definitions
L50 ¼ kdegke RLð Þ
 koff þ ke RLð Þ
kon
Open systems
L50 ¼ koffkon Closed systems
8><
>: ð46Þ
When target baseline levels are the same in two subjects,
i.e. R0; A =R0; B, but one subject, say B as in Fig. 10 has a
higher synthesis rate than A, i.e. ksyn; B > ksyn; A, the
potency of drug in subject B will be numerically higher
than in subject A, because kdeg; B > kdeg; A.
Non-symmetric Drug Distribution Between Central and
Peripheral Compartment
We have seen that when target is located in the
peripheral rather than the central compartment, the
in vivo potency Lc; 50 will depend in the distributional
rates between the two compartments, especially when they
are not equal. Indeed, if Cldα denotes clearance out of the
central compartment and Cldβ clearance into the central
compartment, then, we have shown that if the synthesis
rate of target ksyn is small, the in vivo potency with
respect to the ligand concentration in the central com-
partment Lc; 50 and the in vivo potency with respect to
the peripheral compartment Lp; 50 are related by the
simple formula
Lc;50 ¼ CldβCldα  Lp;50: ð47Þ
Thus, if Cldα >Cldβ relatively easily and high receptor
occupancy will be reached for lower ligand concentrations in
the central compartment, i.e. L50c will be relatively small.
On the other hand, when Cldα <Cldβ ligand has difficulty
reaching the target and the potency, L50; c will now be larger.
We make two observations about the three graphs in
Fig. 10.
1. The graphs appear to be translations of one another
with a constant shift.
2. All three graphs have a larger radius of curvature for
lower values of RLp and a smaller radius of curvature
for higher values of RLp.
As regards the first observation, it follows from Eq. (47)
that





so that the graph shifts by log (Cldβ/Cldα) as we move from
one curve to the next in Fig. 10.
Overall Conclusions
This analysis has focused on the necessity of using an
open systems approach for assessment of in vivo pharmaco-
logical data.
The major difference between potencies of closed and
open systems is that the expression of the latter (L50 in
Eq. (3)) shows that target turnover rate (kdeg) rather than
target concentration (R0) will determine drug potency.
The efficacy (typically denoted Emax/Imax) of a ligand is,
on the other hand, dependent on both target concentra-
tion and target turnover rate. When target is located
peripherally, the ratio of inter-compartmental distribution
(CLdα/CLdβ) impacts the potency derived for a centrally
located target.
Derived expressions are practically and conceptually
applicable when interpreting data translation across individ-
uals, species and studies are done, and also for communica-
tion of results to a biological audience.
Fig. 10. Left: Schematic illustrations of the consequences of two subjects with same the baseline target concentration (R0,A = R0,B), but
different target turnover rates and losses. Right: Relationships between ligand concentration and normalised target occupancy when target
baseline concentration is similar, but fractional turnover rates are different
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APPENDIX 1
Appendix 1.1. Calculations for two targets
When ligand can bind two receptors, R1 and R2, the
way the steady-state concentrations of the two complexes
R1L and R2L depend on the ligand concentration L can
be derived in a manner which very similar to the one
used when only one receptor is present. Thus, we deduce
from the steady-state equations for R1 and R2 in the
system (6) that
R1 ¼ 1kdeg;1 ksyn:1−X1
 




where we have written Xi ¼ ke RiLð ÞRiL (i = 1, 2). Putting the
expression for R1 into the right-hand side of the equation for
dR1L/dt in Eq. (6), and equating it to zero, we obtain
L ksyn;1−X1
  ¼ Km;1 kdeg;1ke R1Lð Þ X1
where
Km;1 ¼
koff ;1 þ ke R1Lð Þ
kon;1
ðA:2Þ
Solving this equation for X1 yields




from which we obtain for R1L and R1:







R1L ¼ R0;1 L50;1Lþ L50;1 ðA:4Þ
the desired expressions given in Eq. (11).
Those for R2L and R2 are derived in a similar fashion.
Appendix 1.2. Calculations for two ligands
When two ligands can bind a single receptor, the
dynamics is described by the system (Eq. (13)), which yields
the following balance equation for ligand at steady state (cf.
Eq. (16)):
ksyn−kdegR−ke RL1ð ÞRL1−ke RL2ð ÞRL2 ¼ 0 ðA:5Þ





where we now write Yi ¼ ke RLið ÞRLi (i = 1, 2).
We substitute this expression for R into the right-
hand sides of each of the last two equations of the full
system (Eq. (13)). Then, we obtain from the one but last
equation in Eq. (13):
L1  1kdeg ksyn−Y1−Y2
  ¼ Km;1 Y1ke RL1ð Þ ðA:7Þ
and for the last equation of Eq. (13):
L2  1kdeg ksyn−Y1−Y2
  ¼ Km;2 Y2ke RL2ð Þ : ðA:8Þ
Equations (A.7) and (A.8) are linear in Y1 and Y2 and
can be solved explicitly. Their solution is




Ai ¼ LiKm;i 
ke RLið Þ
kdeg
; i ¼ 1; 2ð Þ ðA:10Þ
Writing Ai =Li/L50; i (i = 1, 2), the expressions for Y1 and
Y2 in (A.10) yield the following relations between RLi and Li:
RL1 ¼ R1
L1
L1 þ θ  L2 þ L50;1
RL2 ¼ R2
L2
L2 þ θ−1  L1 þ L50;2
ðA:11Þ
where for i = 1, 2,




and θ ¼ L50;1
L50;2
ðA:12Þ
Remark. In the expression for RL1, one can interpret the
term (θ ·L2 +L50; 1) as a Bpotency^ related to L1, and in the
expression for RL2, the term (θ
−1 ·L1 +L50; 2) can be viewed
as a Bpotency^ related to L2.
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Appendix 1.3. Calculations when target is in the peripheral
compartment
The four steady-state concentrations Lc, Lp, R and RLp
solve the following set of four algebraic equations:
kinfus þ μkpcLp−kcpLc−ke Lð ÞLc ¼ 0
μ−1kcpLc−kpcLp−konLp  Rþ koffRLp ¼ 0
ksyn−kdegR−konLp  Rþ koffRLp ¼ 0





where we recall from “TARGET IN THE PERIPHERAL
COMPARTMENT” section that




kcp ¼ CldαVc ; kpc ¼
Cldβ
Vp




We now proceed in two steps: (i) We derive a relation
between the concentrations of complex and ligand in the
peripheral compartment, and then (ii) we derive a compara-
ble relation but between concentrations of the complex in the
peripheral compartment RLp and ligand in the central
compartment Lc.
RLP IN TERMS OF LP
The first equation of Eq. (A.13) yields a relation between
the ligand concentrations in the two compartments:
kinfus þ μ kpcLp− kcp þ ke Lð Þ
 
Lc ¼ 0: ðA:15Þ
Thus,
Lc ¼ a Lp þ b kinfus;
a ¼ μkpc
kcp þ ke Lð Þ
; b ¼ 1
kcp þ ke Lð Þ
ðA:16Þ
We use this expression to eliminate Lc from the second
equation in Eq. (A.13) and so reduce the system to
akcp−μkpc
 
Lp þ b kcpkinfus þ μ −konLp  Rþ koffRLp
  ¼ 0
ksyn−kdegR−konLp  Rþ koffRLp ¼ 0









Lp þ b kcp kinfus−μke RLð ÞRLp ¼ 0 ðA:18Þ
and adding the second and the third equation yields
ksyn ¼ ke RLð ÞRLp þ kdegR ðA:19Þ
We use (A.19) in the fourth equation of Eq. (A.13).
Dividing by kon and multiplying by kdeg yields
Lp  ksyn−ke RLð ÞRLp
  ¼ kdegKm RLp:
When we now divide by ke(RL) and rearrange the terms,
we obtain
RLp ¼ ksynke RLð Þ
Lp




Note that this expression for Lp; 50 is the same as the one
for L50 in Eq. (3).
RLP IN TERMS OF LC
Whereas in the previous part of Appendix 1.3 we
eliminated Lc, R and kinfus, we now eliminate Lp, R and
kinfus. In fact, as before, kinfus is eliminated by means of Eq.
(A.16).
(i) Adding the second and the fourth equation of Eq.
(A.13), we obtain an expression for Lp in therms of
Lc and RLp:
Lp ¼ 1kpc μ
−1kcp Lc−ke RLð ÞRLp
 




(ii) Adding the third and fourth equation of Eq. (A.13)





Finally, we put the expressions for Lp and for R into the








  ¼ Km
ke RLð Þ
X ðA:23Þ
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where X = ke(RL)RLp. Therefore,











Equation (A.25) provides an expression for Lc as a
function of X, i.e. of RLp. Below, we invert this expression
and derive a formula for RLp as a function of Lc by
multiplying Eq. (A.25) by (ksyn −X) and so obtain the
quadratic equation for X:
X2− ksyn þ aLc þ b
 




and b ¼ kdegkpc
ke RLð Þ
Km
This is a quadratic equation in X with roots
X ¼ 12 ksyn þ aLc þ b




Because, we need the root which vanishes when Lc = 0,
i.e. we need X−. Thus,
RLp ¼ 12 ke RLð Þ




ksyn þ aLc þ b











aLc þ bð Þ−
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
ksyn þ aLc þ b





For completeness, we add here the data used in different
simulations. Thus, in Fig. 2, we use the data from Peletier and
Gabrielsson (10) given in Table I and we use them from Cao
and Jusko (18) given in Table II.
The data that have been used in studying the competi-
tion between two targets for a single ligand in Fig. 4 have
been chosen artificially in order to highlight differences
binding coefficients, elimination rates and concentrations of
the two targets. They are given in Table III.
Open Access This article is distributed under the terms
of the Creative Commons Attribution 4.0 International
License (http://creativecommons.org/licenses/by/4.0/), which
permits unrestricted use, distribution, and reproduction in
any medium, provided you give appropriate credit to the
original author(s) and the source, provide a link to the
Creative Commons license, and indicate if changes were
made.
Table I. Parameter Values of Peletier and Gabrielsson (10)
kon koff ksyn kdeg Cl(L) Cld ke(RL) R0 R∗ Vc Vt
0.091 0.001 0.1 0.0089 0.001 0.003 0.003 12 36 0.05 0.1
(L/kg)/h 1/h (mg/L)/h 1/h (mg/L)/h (mg/L)/h 1/h mg/L mg/L L/kg L/kg
Table III. Parameter Values for Fig. 4
R0 kon koff ksyn kdeg ke(RL) R
∗
Receptor 1 100 0.753 14.6 69.4 0.694 3.93 17.6
Receptor 2 50 1.5 14.6 35 0.694 3.93 8.9
nM {(nM)day}-1 day-1 nM day-1 day-1 day-1 nM
Table II. Parameter Values of Cao and Jusko (18)
ke(L) kon koff ksyn kdeg ke(RL) R0 R∗ V
0.00038 0.1 0.001 0.1 0.01 0.03 10 3.3 2.6
h-1 {(nM)h}-1 h-1 (nM)/h h-1 h-1 nM nM L
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